Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Big Pharma's vaccine land grab

Big Pharma's vaccine land grab

Money Moves

As aging populations drive a $37 billion adult immunization boom, pharmaceutical giants are buying their way into the market

June 1st, 2025: Curevo Enrolls First Patients in Phase 2 Extension

Overview

Sanofi dropped $2.2 billion on December 24, 2025 to acquire Dynavax, a California biotech with a two-dose hepatitis B vaccine and a shingles vaccine in development. The 39% premium signals desperation in a market projected to hit $37.2 billion by 2033, driven by aging populations; the deal is expected to close in Q1 2026 pending Hart-Scott-Rodino antitrust clearance.[1] By 2050, 2.1 billion people will be over 60, triple the population over 80.

GSK controls 94% of the $4.9 billion shingles market with Shingrix. Curevo raised $110 million in March 2025 and launched Phase 2 trials of amezosvatein, a shingles vaccine showing zero severe side effects versus Shingrix's debilitating reactogenicity. Merck paid $9.2 billion for Cidara's flu antiviral.

The Sanofi-Dynavax deal is the latest in a consolidation wave in the vaccine industry, with new competitors emerging. PwC's 2026 M&A outlook identifies the deal as emblematic of pharma's strategy to fill pipeline gaps and reposition portfolios against patent cliffs.[3] Big Pharma sees vaccine portfolios as insurance against patent cliffs and is buying every promising asset before rivals do.

Play on this story Voices Debate Who Said What? Predict

Key Indicators

$2.2B
Sanofi-Dynavax Deal Value
39% premium over prior close, doubling Sanofi's adult vaccine capabilities
46%
HEPLISAV-B Market Share
Dynavax's hep B vaccine now captures nearly half the U.S. market
$37.2B
Adult Vaccine Market by 2033
Up from $21.8B in 2024, fueled by aging demographics and immunosenescence
2.1B
Global Population 60+ by 2050
Nearly doubling from 1B in 2020, with 80+ cohort tripling to 426M
94%
GSK's Shingrix Dominance
Near-monopoly on $4.9B shingles market creates acquisition urgency

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 6 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Timeline Five events from this story — drag them oldest to newest. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Ryan Spencer
Ryan Spencer
Leading company through $2.2B acquisition by Sanofi
 Thomas Triomphe
Thomas Triomphe
Leading Sanofi's vaccine expansion strategy

Organizations Involved

Sanofi
Sanofi
Pharmaceutical Company
Acquiring Dynavax to strengthen adult vaccine portfolio

French pharma giant racing to build a €10 billion vaccine business by 2030 through aggressive M&A.
Dynavax Technologies
Dynavax Technologies
Biopharmaceutical company
Being acquired by Sanofi for $2.2 billion

California biotech that built a hepatitis B vaccine franchise and supplies adjuvants to vaccine makers globally.
GSK (GlaxoSmithKline)
GSK (GlaxoSmithKline)
Multinational pharmaceutical company
Market leader in adult vaccines, defending shingles monopoly

British pharma giant controlling 94% of the shingles vaccine market with Shingrix, setting the competitive bar Sanofi aims to challenge.
Curevo Vaccine
Curevo Vaccine
Biopharmaceutical company
Developing amezosvatein shingles vaccine with superior tolerability profile, Phase 2 extension ongoing

Biotech developing next-generation shingles vaccine targeting GSK's near-monopoly through superior tolerability.
Merck & Co.
Merck & Co.
Pharmaceutical company
Expanding infectious disease portfolio through $9.2B Cidara acquisition

Pharmaceutical giant pivoting toward respiratory vaccines and antivirals as traditional small-molecule drugs face patent cliffs.

Timeline

May 2024 June 2025

14 events Latest: June 1st, 2025 · 12 months ago Showing 8 of 14
Tap a bar to jump to that date

  1. Curevo Enrolls First Patients in Phase 2 Extension

    Latest Clinical Development

    Phase 2 extension trial targeting 640 adults over age 70, head-to-head versus Shingrix, aiming to validate superior tolerability profile in oldest patients.

  2. Curevo Raises $110M for Shingles Vaccine

    Financing

    Series B round led by Medicxi with participation from OrbiMed, Sanofi Ventures, and others to advance amezosvatein through Phase 2 extension and prepare for Phase 3 pivotal trials.

  3. Curevo Reports Sustained Amezosvatein Immunogenicity

    Clinical Development

    Updated Phase 2 data shows amezosvatein antibody levels remained non-inferior to Shingrix one year after second dose, with zero Grade 3 side effects vs 19.1% Grade 2+ systemic reactions for Shingrix.

  4. Merck Acquires Cidara for $9.2 Billion

    Acquisition

    Merck pays $221.50/share for Cidara Therapeutics to gain CD388, a late-stage flu antiviral candidate positioning as universal alternative to traditional flu vaccines.

  5. Sanofi Announces Dynavax Acquisition

    Acquisition

    Sanofi agrees to acquire Dynavax for $15.50/share cash ($2.2B total), adding HEPLISAV-B and shingles candidate to portfolio. Stock surges 39%.

  6. HEPLISAV-B Achieves Record Revenue

    Commercial Milestone

    Dynavax announces preliminary Q4 2024 results: HEPLISAV-B achieved record annual revenue of $268.4 million, reflecting 26% year-over-year growth.

  7. GSK Reduces China Shingrix Deliveries

    Market Development

    GSK extends Zhifei partnership to 11 years but significantly reduces planned deliveries—21.6 billion yuan over 2024-2029 vs original 20.6 billion yuan over just 2024-2026, signaling demand concerns.

  8. HEPLISAV-B Hits 46% Market Share

    Commercial Milestone

    Dynavax reports HEPLISAV-B captured 46% of U.S. hepatitis B vaccine market in Q3, up from 44% in 2023.

  9. Dynavax Presents Z-1018 Data at IDWeek

    Clinical Development

    Dynavax presents detailed Phase 1/2 data at IDWeek 2025 conference and announces initiation of Part 2 trial in adults 70+ years old.

  10. BioNTech Acquires CureVac

    Acquisition

    BioNTech announces $1.25 billion all-stock acquisition of CureVac, consolidating mRNA vaccine development capabilities.

  11. Z-1018 Phase 1/2 Shows Superior Tolerability

    Clinical Development

    Dynavax reports positive results: Z-1018 demonstrated comparable immunogenicity to Shingrix with significantly fewer side effects—12.5% vs 52.6% reported severe local reactions, 27.5% vs 63.2% severe systemic reactions.

  12. GSK-CureVac $1.4B mRNA Deal

    Deal

    GSK enters $1.4 billion licensing agreement with CureVac for next-generation mRNA vaccines targeting flu, COVID-19, and avian flu.

  13. Dynavax Begins Shingles Vaccine Trial

    Clinical Development

    Dynavax doses first patient in Phase 1/2 trial of Z-1018 shingles vaccine candidate.

  14. Novavax-Sanofi COVID Vaccine Partnership

    Deal

    Sanofi and Novavax announce co-exclusive licensing for COVID-19 vaccine and combination shots, signaling Sanofi's vaccine expansion strategy.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2009

Pfizer's Acquisition of Wyeth (2009)

During the financial crisis, Pfizer paid $68 billion for Wyeth, largely to acquire its vaccine portfolio including Prevnar (pneumococcal). The deal gave Pfizer critical mass in vaccines at a time when primary-care blockbusters faced patent cliffs and pricing pressure.

Then

Prevnar became one of Pfizer's top revenue generators, validating the vaccine bet.

Now

Established the playbook: acquire vaccine assets during market uncertainty to diversify from small-molecule drugs facing patent expiration and political pricing pressure.

Why this matters now

Sanofi is following the same script—facing patent cliffs, it's buying commercial vaccine products and pipeline candidates to sustain growth as traditional drugs lose exclusivity.

2017-present

GSK's Shingrix Launch Disrupts Market (2017)

GSK launched Shingrix with >90% efficacy, instantly obsoleting Merck's live-virus Zostavax. Within three years, Shingrix captured 94% market share and generated £3+ billion annually, demonstrating how clinical superiority can create near-monopolies in adult vaccines.

Then

Merck withdrew Zostavax from the U.S. market by 2020, ceding the field entirely to GSK.

Now

Every major pharma launched shingles programs to challenge GSK, including Pfizer/BioNTech (mRNA), Curevo (reduced side effects), and now Sanofi via Dynavax acquisition.

Why this matters now

The Dynavax shingles candidate represents Sanofi's attempt to replicate GSK's playbook—use superior technology (CpG 1018 adjuvant) to differentiate and capture market share from an entrenched incumbent.

2020-2021

COVID-19 Vaccine mRNA Gold Rush (2020-2021)

Pfizer/BioNTech and Moderna generated $75+ billion in COVID vaccine revenue, proving mRNA technology could produce safe, effective vaccines at unprecedented speed. Traditional vaccine makers like Sanofi watched from the sidelines as biotech upstarts captured windfall profits.

Then

Big Pharma launched acquisition spree to acquire mRNA capabilities—Sanofi bought Translate Bio ($3.2B), GSK partnered with CureVac ($1.4B), BioNTech acquired CureVac ($1.25B).

Now

Vaccine development bifurcated into mRNA platforms (faster, flexible) and traditional approaches (adjuvants, recombinant proteins), with companies hedging by investing in both.

Why this matters now

The Dynavax deal shows Sanofi hasn't fully committed to mRNA—it's diversifying with proven adjuvant technology, betting both platforms will coexist in a market where speed, efficacy, and tolerability all matter.

Sources

(31)
+25
Sanofi Bloomberg Yahoo Finance PredictStreet Pharmaceutical Technology RTT News Grand View Research PharmaVoice GlobeNewswire Dynavax Technologies Fierce Pharma BioPharma Dive Drug Discovery Trends Seeking Alpha The Motley Fool PR Newswire MedCity News Trefis Xtalks Curevo Vaccine Longevity (Vocal Media) PwC Dynavax Technologies Dynavax Technologies Fierce Pharma Seeking Alpha Pharmaceutical Technology GlobeNewswire GlobeNewswire GlobeNewswire Pharmaceutical Technology